Relief Therapeutics Holding SA
SIX:RLF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Relief Therapeutics Holding SA
SIX:RLF
|
CH |
|
E
|
Energix Renewable Energies Ltd
TASE:ENRG
|
IL |
|
P
|
Peakstone Realty Trust
NYSE:PKST
|
US |
|
B
|
Bank of America Corp
SIX:BAC
|
US |
|
Contextlogic Inc
NASDAQ:LOGC
|
US |
|
M
|
Motherson Sumi Wiring India Ltd
NSE:MSUMI
|
IN |
|
Crown Capital Partners Inc
TSX:CRWN
|
CA |
|
Shanghai Belling Corp Ltd
SSE:600171
|
CN |
|
F
|
Fosun Tourism Group
HKEX:1992
|
CN |
|
CMO Group PLC
LSE:CMO
|
UK |
|
C
|
CSP International Fashion Group SpA
MIL:CSP
|
IT |
|
Pan Global Resources Inc
XTSX:PGZ
|
CA |
Relief Therapeutics Holding SA
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
